

Neuren (NEU) – ASX Announcement**6 November 2024****Priority Review Voucher sold for US\$150m – Neuren to receive one third****Highlights:**

- **Acadia Pharmaceuticals entered into agreement to sell Rare Pediatric Disease Priority Review Voucher (PRV) for US\$150m**
- **Neuren is entitled to receive one-third of the net proceeds**

Melbourne, Australia: Neuren Pharmaceuticals (ASX: NEU) today announced that its partner Acadia Pharmaceuticals (NASDAQ: ACAD) has entered into a definitive asset purchase agreement to sell the Rare Pediatric Disease Priority Review Voucher (PRV) for US\$150m upon the closing of the transaction. The transaction is subject to customary closing conditions, including expiration of applicable waiting period under the Hart-Scott Rodino (HSR) Antitrust Improvements Act.

The PRV was granted by the U.S. Food and Drug Administration (FDA) following the approval of DAYBUE™ (trofinetide) for the treatment of Rett syndrome. Under the license agreement between Acadia and Neuren, Neuren is entitled to receive one-third of the proceeds, net of any applicable costs, which are not expected to be material.

About Neuren

Neuren is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. Recognising the urgent unmet need, all programs have been granted “orphan drug” designation in the United States. Orphan drug designation provides incentives to encourage development of therapies for rare and serious diseases.

DAYBUE™ (trofinetide) is approved by the US Food and Drug Administration (FDA) for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. Neuren has granted an exclusive worldwide licence to Acadia Pharmaceuticals Inc. for the development and commercialisation of trofinetide.

Neuren’s second drug candidate, NNZ-2591, is in Phase 2 development for multiple neurodevelopmental disorders, with positive results achieved in Phase 2 clinical trials in Phelan-McDermid syndrome, Pitt Hopkins syndrome and Angelman syndrome.

Contact:

investorrelations@neurenpharma.com

Jon Pilcher, CEO: +61 438 422 271

ASX Listing Rules information

This announcement was authorized to be given to the ASX by the board of directors of Neuren Pharmaceuticals Limited, Suite 201, 697 Burke Road, Camberwell, VIC 3124



pharmaceuticals

Forward-looking Statements

This announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Neuren to be materially different from the statements in this announcement.